| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2019-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6963d575ba9a9cb819603cdda2259d93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_457aac9ad18e13cc44a15d1cfaa62b21 |
| publicationDate |
2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019227081-A1 |
| titleOfInvention |
Procalcitonin for the prognosis of adverse events |
| abstract |
The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11143659-B2 |
| priorityDate |
2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |